Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Loncastuximab tesirine: a novel antibody-drug conjugate for DLBCL

Carmelo Carlo-Stella • 21 Jun 2020
EHA 2020
Aggressive & Diffuse Large B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Loncastuximab tesirine

Carmelo Carlo-Stella, MD, PhD, of Humanitas Clinical and Research Center, Rozzano, Italy, discusses initial results of a Phase II study of loncastuximab tesirine, a novel antibody-drug conjugate targeting CD19, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Carmelo Carlo-Stella

Approaching the treatment of patients with LBCL who relapse after bispecific antibodies 2:38
Approaching the treatment of patients with LBCL who relapse after bispecific antibodies
Carmelo Carlo-Stella • 21 Jun 2024
How to manage tumor flare after administration of bispecific antibodies 1:51
How to manage tumor flare after administration of bispecific antibodies
Carmelo Carlo-Stella • 21 Jun 2024
The role of TP53 & ctDNA kinetics in patients with R/R LBCL treated with glofitamab monotherapy 5:04
The role of TP53 & ctDNA kinetics in patients with R/R LBCL treated with glofitamab monotherapy
Carmelo Carlo-Stella • 21 Jun 2024
Important practical considerations for the use of glofitamab for DLBCL 2:21
Important practical considerations for the use of glofitamab for DLBCL
Carmelo Carlo-Stella • 20 Oct 2023

Related Videos

A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL 1:58
A retrospective study of Pola-R-CHP versus R+DA-EPOCH in high-risk DLBCL
Rahul Thakur • 8 Dec 2025
Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO 2:24
Glofitamab-GemOx versus R-GemOx in transplant-ineligible R/R DLBCL: subgroup analysis of STARGLO
Haifaa Abdulhaq • 8 Dec 2025
Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7 2:53
Epcoritamab + R2 or epcoritamab maintenance in 1L FL: 3-year outcomes from EPCORE NHL-2 arms 6 & 7
Lori Leslie • 7 Dec 2025
Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL 1:35
Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL
Marc Hoffman • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals